MAP Pharmaceuticals News

STOCK MARKETING INC PRESENTS : Source Gold Corp., MAP Pharmaceuticals, Inc., San West, Inc., Helicos BioSciences Corp., eDOORWAYS Corp., Bryn Resources, Inc.

Alan Petro to the newly created position of vice president, Manufacturing and Technical Operations at MAP Pharmaceuticals .

MAP Pharmaceuticals, Inc. today announced that it has secured a committed equity financing facility under which it may sell up to $60 million of its registered common stock to Azimuth Opportunity Ltd.

CFO of MAP PHARMACEUTICALS, INC. Christopher Y Chai sells 10,000 shares of MAPP on 10/01/2009 at an average price of $10.26 a share.

MAP Pharmaceuticals Inc. plans to share additional data from testing of its migraine drug candidate Levadex next week, and a Wedbush Morgan analyst said the results could boost MAP's share price.

The multi-center, phase three FREEDOM-301 trial for the orally-inhaled migraine therapy, LEVADEX, shows study participants had significant relief from symptoms such as pain, nausea and light and sound sensitivity when compared to placebo treatment.

Investors can't seem to get enough of the huge payoff potential of investing in the Biotechnology industry, as the industry starts to raise capital once again various types of equity offerings.

MAP Pharmaceuticals Inc. said Thursday it priced an offer of 3.5 million shares of stock at $9.70 per share, raising $31.4 million after expenses.

A new study conducted at the Jefferson Headache Center at Thomas Jefferson University Hospital in Philadelphia, Pennsylvania shows an investigational, orally-inhaled therapy is effective in treating migraines.

A new study conducted at the Jefferson Headache Center at Thomas Jefferson University Hospital in Philadelphia, Pennsylvania shows an investigational, orally-inhaled therapy is effective in treating migraines.

MAP Pharmaceuticals Inc. said Thursday it priced an offer of 3.5 million shares of stock at $9.70 per share, raising $31.4 million after expenses.

MAP Pharmaceuticals Inc. said Thursday it priced an offer of 3.5 million shares of stock at $9.70 per share, raising $31.4 million after expenses.

MAP Pharmaceuticals Inc. said Thursday it priced an offer of 3.5 million shares of stock at $9.70 per share, raising $31.4 million after expenses.

MAP Pharmaceuticals, Inc. announced today its intention, subject to market and other conditions, to offer 3,500,000 shares of its common stock in a registered public offering pursuant to its existing shelf registration statement.

MAP Pharmaceuticals Inc. reported a second quarter loss Monday of $5 million, or 24 cents a share, narrowed from a loss of $16.5 million, or 81 cents a share in the same quarter last year.

MAP Pharmaceuticals, Inc. today announced financial results for the second quarter ended June 30, 2009.

MAP Pharmaceuticals, Inc. has announced that it has received a notice of termination of the license agreement with AstraZeneca related to the company's Unit Dose Budesonide product candidate.

Shares of MAP Pharmaceuticals Inc. continued their rapid ascent Wednesday as Wall Street assessed the company's migraine drug candidate, Levadex, following a successful clinical trial.

Shares in MAP Pharmaceuticals Inc. spiked 185.7 percent Tuesday on the news that its Phase III migraine study of Levadex hit all four primary objectives.

MAP Pharmaceuticals, Inc. announced today that the efficacy portion of its first Phase 3 clinical trial evaluating its novel LEVADEX orally inhaled migraine therapy met all four primary endpoints.